NASDAQ: VERA
Vera Therapeutics Inc Stock

$24.00+0.59 (+2.52%)
Updated Apr 29, 2025
VERA Price
$24.00
Fair Value Price
$0.69
Market Cap
$1.53B
52 Week Low
$18.53
52 Week High
$51.61
P/E
-8.73x
P/B
2.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$152.15M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$135M
Beta
1.12
Next Earnings
May 15, 2025
Ex-Dividend
N/A
Next Dividend
N/A

VERA Overview

Vera Therapeutics, Incorporated develops treatments for patients with serious immunological diseases in the U.S. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. Known as Trucode Gene Repair, Inc. until 2020, Vera Therapeutics was incorporated in 2016 and is headquartered in Brisbane, CA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine VERA's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
VERA
Ranked
#362 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important VERA news, forecast changes, insider trades & much more!

VERA News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VERA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VERA ($24.00) is overvalued by 3,393.58% relative to our estimate of its Fair Value price of $0.69 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VERA ($24.00) is not significantly undervalued (3,393.58%) relative to our estimate of its Fair Value price of $0.69 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VERA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VERA due diligence checks available for Premium users.

Valuation

VERA fair value

Fair Value of VERA stock based on Discounted Cash Flow (DCF)

Price
$24.00
Fair Value
$0.69
Overvalued by
3,393.58%
VERA ($24.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VERA ($24.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VERA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VERA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-8.73x
Industry
-158.75x
Market
29.19x

VERA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.65x
Industry
4.37x
VERA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VERA's financial health

Profit margin

Revenue
$0.0
Net Income
-$43.4M
Profit Margin
0%
VERA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$655.7M
Liabilities
$78.5M
Debt to equity
0.14
VERA's short-term assets ($651.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VERA's short-term assets ($651.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VERA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VERA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$39.2M
Investing
-$221.4M
Financing
$326.0M
VERA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VERA vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
VERAD$1.53B+2.52%-8.73x2.65x
IMCRC$1.53B-0.46%-29.87x4.23x
MNKDB$1.49B+3.81%49.10x-18.91x
GPCRD$1.48B+9.70%-11.07x1.72x
EWTXD$1.47B-1.40%-10.66x3.21x

Vera Therapeutics Stock FAQ

What is Vera Therapeutics's quote symbol?

(NASDAQ: VERA) Vera Therapeutics trades on the NASDAQ under the ticker symbol VERA. Vera Therapeutics stock quotes can also be displayed as NASDAQ: VERA.

If you're new to stock investing, here's how to buy Vera Therapeutics stock.

What is the 52 week high and low for Vera Therapeutics (NASDAQ: VERA)?

(NASDAQ: VERA) Vera Therapeutics's 52-week high was $51.61, and its 52-week low was $18.53. It is currently -53.5% from its 52-week high and 29.52% from its 52-week low.

How much is Vera Therapeutics stock worth today?

(NASDAQ: VERA) Vera Therapeutics currently has 63,748,290 outstanding shares. With Vera Therapeutics stock trading at $24.00 per share, the total value of Vera Therapeutics stock (market capitalization) is $1.53B.

Vera Therapeutics stock was originally listed at a price of $11.50 in May 14, 2021. If you had invested in Vera Therapeutics stock at $11.50, your return over the last 3 years would have been 108.7%, for an annualized return of 27.79% (not including any dividends or dividend reinvestments).

How much is Vera Therapeutics's stock price per share?

(NASDAQ: VERA) Vera Therapeutics stock price per share is $24.00 today (as of Apr 29, 2025).

What is Vera Therapeutics's Market Cap?

(NASDAQ: VERA) Vera Therapeutics's market cap is $1.53B, as of Apr 30, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vera Therapeutics's market cap is calculated by multiplying VERA's current stock price of $24.00 by VERA's total outstanding shares of 63,748,290.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.